NMTC2
MCID: THY102
MIFTS: 63

Thyroid Cancer, Nonmedullary, 2 (NMTC2)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 2

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 2:

Name: Thyroid Cancer, Nonmedullary, 2 58
Follicular Thyroid Carcinoma 12 54 30 6 15 17 74
Thyroid Carcinoma, Follicular 58 77 54 13
Thyroid Cancer, Follicular 54 74
Nmtc2 58 76
Follicular Adenocarcinoma, Well Differentiated 12
Follicular Carcinoma of the Thyroid Gland 12
Thyroid Carcinoma, Follicular, Somatic 58
Cancer, Thyroid, Nonmedullary, Type 2 41
Thyroid Cancer, Non-Medullary, 2 76
Thyroid Follicular Carcinoma 56
Thyroid Gland Adenocarcinoma 74
Adenocarcinoma, Follicular 45
Follicular Adenocarcinoma 12
Follicular Thyroid Cancer 56
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12
Ftc 54

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation


HPO:

33
thyroid cancer, nonmedullary, 2:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:3962
OMIM 58 188470
NCIt 51 C8054
SNOMED-CT 69 28173006 5257006
SNOMED-CT via HPO 70 124975008 255028004 263681008

Summaries for Thyroid Cancer, Nonmedullary, 2

OMIM : 58 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550). (188470)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 2, also known as follicular thyroid carcinoma, is related to differentiated thyroid carcinoma and hyperthyroidism. An important gene associated with Thyroid Cancer, Nonmedullary, 2 is SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), and among its related pathways/superpathways are Focal Adhesion and Endometrial cancer. The drugs Iodine and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and brain, and related phenotypes are abnormality of metabolism/homeostasis and follicular thyroid carcinoma

Disease Ontology : 12 A thyroid carcinoma that has material basis in follicular cells.

UniProtKB/Swiss-Prot : 76 Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 77 Follicular thyroid cancer accounts for 15% of thyroid cancer and occurs more commonly in women over 50... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 2

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 1 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 differentiated thyroid carcinoma 32.7 BRAF HRAS NKX2-1 NRAS PAX8 PPARG
2 hyperthyroidism 31.0 TG THRB TSHR
3 graves disease 1 30.8 DIO2 TG THRB TSHR
4 goiter 30.8 CALCA LGALS3 NKX2-1 PAX8 TG THRB
5 multinodular goiter 30.6 CALCA HRAS NKX2-1 PAX8 TG TSHR
6 papillary carcinoma 30.5 BRAF CALCA LGALS3 NKX2-1 PAX8 RET
7 thyroid cancer 30.4 BRAF CALCA DIO2 HRAS KDR LGALS3
8 follicular adenoma 30.4 CALCA LGALS3 NKX2-1 PAX8 PTEN RET
9 thyroid carcinoma, familial medullary 30.4 CALCA NKX2-1 RET TG
10 giant congenital nevus 30.4 HRAS NRAS
11 struma ovarii 30.4 BRAF NKX2-1 RET TG TSHR
12 thyroiditis 30.4 CALCA RET TG THRB TSHR
13 adenocarcinoma 30.4 BRAF HRAS KDR PTEN RET
14 nontoxic goiter 30.3 CALCA TG TSHR
15 malignant struma ovarii 30.3 HRAS LGALS3 NKX2-1 NRAS RET TG
16 testicular germ cell tumor 30.3 BRAF HRAS PTEN
17 ovarian germ cell teratoma 30.2 NKX2-1 NRAS RET TG
18 renal cell carcinoma, papillary, 1 30.2 BRAF HRAS NRAS PAX8 PTEN
19 gastric adenocarcinoma 30.1 BRAF HRAS KDR NRAS PTEN
20 hypothyroidism 29.8 CALCA DIO2 NKX2-1 PAX8 RET TG
21 familial papillary or follicular thyroid carcinoma 12.3
22 trabecular follicular adenocarcinoma 12.3
23 papillary follicular thyroid adenocarcinoma 12.2
24 tumoral calcinosis, hyperphosphatemic, familial, 1 11.7
25 thyroid carcinoma, hurthle cell 11.3
26 tumoral calcinosis, hyperphosphatemic, familial, 2 11.1
27 tumoral calcinosis, hyperphosphatemic, familial, 3 11.1
28 ovarian melanoma 10.5 HRAS NRAS PTEN
29 mucoepidermoid thyroid carcinoma 10.5 CALCA TG
30 chromosome 14q11-q22 deletion syndrome 10.5 HRAS NKX2-1
31 thyroid cancer, nonmedullary, 1 10.5
32 suppurative thyroiditis 10.5 CALCA TG
33 ovarian serous cystadenocarcinoma 10.5 BRAF HRAS NRAS
34 leukemia, chronic lymphocytic 2 10.5 BRAF HRAS NRAS
35 giant cell glioblastoma 10.5 BRAF PPARG PTEN
36 ovarian germ cell cancer 10.5 NKX2-1 RET TG
37 colloid adenoma 10.5 LGALS3 NKX2-1 TG
38 thyroid sarcoma 10.5 CALCA TG
39 toxic diffuse goiter 10.5 DIO2 TG TSHR
40 schimmelpenning-feuerstein-mims syndrome 10.5 HRAS NRAS
41 ovarian cystic teratoma 10.5 CALCA NKX2-1 TG
42 melanoma, cutaneous malignant 1 10.5 BRAF HRAS NRAS PTEN
43 water-clear cell adenoma 10.5 PAX8 TG
44 respiratory system cancer 10.5 HRAS NKX2-1 PTEN
45 small cell carcinoma 10.5 CALCA NKX2-1 PTEN
46 parathyroid carcinoma 10.5 CALCA LGALS3 RET
47 suppression of tumorigenicity 12 10.4 BRAF HRAS PTEN
48 mixed type thymoma 10.4 PAX8 PTEN
49 athyreosis 10.4 NKX2-1 PAX8 TG TSHR
50 gastrointestinal system cancer 10.4 HRAS KDR PTEN

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 2:



Diseases related to Thyroid Cancer, Nonmedullary, 2

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 2

Human phenotypes related to Thyroid Cancer, Nonmedullary, 2:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 33 HP:0001939
2 follicular thyroid carcinoma 33 HP:0006731
3 non-medullary thyroid carcinoma 33 HP:0040198

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
nonmedullary thyroid carcinoma (papillary and follicular)

Clinical features from OMIM:

188470

GenomeRNAi Phenotypes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.03 HRAS
2 Decreased viability GR00221-A-1 10.03 HRAS KDR NRAS PPARG RET
3 Decreased viability GR00221-A-2 10.03 HRAS KDR PPARG RET
4 Decreased viability GR00221-A-3 10.03 HRAS KDR NRAS PPARG
5 Decreased viability GR00221-A-4 10.03 KDR PPARG RET
6 Decreased viability GR00231-A 10.03 RET
7 Decreased viability GR00301-A 10.03 RET
8 Decreased viability GR00402-S-2 10.03 HRAS KDR NRAS PPARG RET
9 Reduced mammosphere formation GR00396-S 9.17 BRAF HRAS KDR NRAS PAX8 PPARG

MGI Mouse Phenotypes related to Thyroid Cancer, Nonmedullary, 2:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.38 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
2 behavior/neurological MP:0005386 10.36 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
3 homeostasis/metabolism MP:0005376 10.36 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
4 endocrine/exocrine gland MP:0005379 10.33 BRAF DIO2 HRAS NKX2-1 NRAS PAX8
5 cardiovascular system MP:0005385 10.32 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
6 cellular MP:0005384 10.31 BRAF KDR LGALS3 NKX2-1 NRAS PAX8
7 digestive/alimentary MP:0005381 10.26 BRAF DIO2 HRAS LGALS3 NKX2-1 NRAS
8 mortality/aging MP:0010768 10.26 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
9 hematopoietic system MP:0005397 10.22 BRAF KDR LGALS3 NRAS PPARG PTEN
10 nervous system MP:0003631 10.21 BRAF HRAS KDR LGALS3 NKX2-1 PAX8
11 neoplasm MP:0002006 10.16 BRAF HRAS LGALS3 NKX2-1 NRAS PPARG
12 limbs/digits/tail MP:0005371 10.1 BRAF NRAS PAX8 PTEN RET TG
13 adipose tissue MP:0005375 10.07 BRAF DIO2 LGALS3 PPARG PTEN TG
14 normal MP:0002873 10.07 BRAF HRAS KDR MINPP1 NKX2-1 NRAS
15 no phenotypic analysis MP:0003012 10.01 HRAS KDR NKX2-1 NRAS PAX8 PPARG
16 renal/urinary system MP:0005367 9.92 BRAF DIO2 HRAS LGALS3 PAX8 PPARG
17 reproductive system MP:0005389 9.91 BRAF LGALS3 NKX2-1 PAX8 PPARG PTEN
18 skeleton MP:0005390 9.77 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
19 respiratory system MP:0005388 9.76 BRAF HRAS KDR LGALS3 NKX2-1 PTEN
20 vision/eye MP:0005391 9.23 BRAF KDR NRAS PAX8 PPARG PTEN

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 2

Drugs for Thyroid Cancer, Nonmedullary, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
2 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
3 Hormones Phase 3,Phase 2,Phase 1
4 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
5 Nutrients Phase 2, Phase 3,Phase 1,Not Applicable
6 Micronutrients Phase 2, Phase 3,Phase 1,Not Applicable
7 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
8 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
10 Hormone Antagonists Phase 3,Phase 2
11
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
14
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
15
Indinavir Approved Phase 2 150378-17-9 5362440
16
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
17
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
18
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
19
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
20
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
21
Lithium carbonate Approved Phase 2 554-13-2
22
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
23
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
24
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
25
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
26
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
27
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
28
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
29
Sodium Citrate Approved, Investigational Phase 2 68-04-2
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
32
Tamoxifen Approved Phase 2 10540-29-1 2733526
33
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
34
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
35
Lenvatinib Approved, Investigational Phase 2 417716-92-8
36
Durvalumab Approved, Investigational Phase 2 1428935-60-7
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
Trametinib Approved Phase 2 871700-17-3 11707110
39
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
40
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
41
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
42
Ipilimumab Approved Phase 2 477202-00-9
43
nivolumab Approved Phase 2 946414-94-4
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
46
Maleic acid Experimental, Investigational Phase 2,Phase 1 110-17-8, 110-16-7 444972
47
Imetelstat Investigational Phase 2 868169-64-6
48
Doxil Approved June 1999 Phase 2 31703
49
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
50
Tremelimumab Investigational Phase 2 745013-59-6

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
2 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
3 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
4 High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
5 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
6 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
7 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
8 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
9 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
10 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
11 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
12 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
13 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
14 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer Completed NCT00181168 Phase 2 Euthyroid Group
15 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
16 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
17 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
18 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
19 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
20 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
21 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
22 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
23 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
24 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
25 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
26 Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
27 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
28 Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
29 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
30 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
31 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
32 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2 Lenalidomide
33 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Active, not recruiting NCT00537095 Phase 2 Vandetanib
34 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
35 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Active, not recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
36 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
37 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
38 Cabozantinib, Nivolumab, and Ipilimumab in Treating Patients With Radioactive Iodine-Refractory Differentiated Thyroid Cancer That Progressed After VEGFR-Targeted Therapy Not yet recruiting NCT03914300 Phase 2 Cabozantinib;Cabozantinib S-malate
39 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
40 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
41 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed NCT00004062 Phase 1 azacitidine;liothyronine sodium
42 Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Completed NCT01413113 Phase 1 pazopanib hydrochloride
43 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
44 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
45 Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
46 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
47 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
48 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
49 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
50 Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Completed NCT01433809

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 2

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Cancer, Nonmedullary, 2

Genetic tests related to Thyroid Cancer, Nonmedullary, 2:

# Genetic test Affiliating Genes
1 Follicular Thyroid Carcinoma 30 HRAS MINPP1 NRAS SRGAP1

Anatomical Context for Thyroid Cancer, Nonmedullary, 2

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 2:

42
Thyroid, Lymph Node, Brain, Pituitary, Kidney, Skin, Endothelial

Publications for Thyroid Cancer, Nonmedullary, 2

Articles related to Thyroid Cancer, Nonmedullary, 2:

(show top 50) (show all 448)
# Title Authors Year
1
Pulmonary metastasis of mesonephric-like adenocarcinoma arising from the uterine body: a striking mimic of follicular thyroid carcinoma. ( 30471132 )
2019
2
Differences of HBME-1 Expression in Thyroid Follicular Adenoma and Follicular Thyroid Carcinoma by Ultrasound-Guided Fine-Needle Aspiration Biopsy. ( 30925956 )
2019
3
Spectroscopic identification of benign (follicular adenoma) and cancerous lesions (follicular thyroid carcinoma) in thyroid tissues. ( 30954022 )
2019
4
Synchronous primary hyperparathyroidism, follicular thyroid carcinoma, and papillary thyroid carcinoma. ( 30614854 )
2019
5
A case of follicular thyroid carcinoma associated with phosphatase and tensin homologue hamartoma tumour syndrome. ( 30575166 )
2019
6
Follicular thyroid carcinoma metastatic to skin: a small papule and a big diagnostic change. ( 30726467 )
2019
7
Fine-needle aspiration cytology of metastatic spindle cell follicular thyroid carcinoma: A case report. ( 30794342 )
2019
8
Prediction of follicular thyroid carcinoma associated with distant metastasis in the preoperative and postoperative model. ( 30891875 )
2019
9
Follicular Thyroid Carcinoma Presenting as a Manubrium Mass. ( 30973599 )
2019
10
In Silico Integration Approach Reveals Key MicroRNAs and Their Target Genes in Follicular Thyroid Carcinoma. ( 31032340 )
2019
11
Development and validation of a preoperative prediction model for follicular thyroid carcinoma. ( 31050007 )
2019
12
Molecular Signature of Prospero Homeobox 1 (PROX1) in Follicular Thyroid Carcinoma Cells. ( 31060342 )
2019
13
Perfluorooctanoic Acid Enhances Invasion of Follicular Thyroid Carcinoma Cells Through NF-κB and Matrix Metalloproteinase-2 Activation. ( 31092435 )
2019
14
Surgical management of follicular thyroid carcinoma in children and adolescents: A study of 30 cases. ( 29935896 )
2019
15
Tumour growth rate of follicular thyroid carcinoma is not different from that of follicular adenoma. ( 29509975 )
2018
16
A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. ( 29298844 )
2018
17
Pulmonary Vein Thrombosis Associated with Metastatic Follicular Thyroid Carcinoma: A Case Report and Review. ( 30112241 )
2018
18
TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma. ( 30306386 )
2018
19
Preoperative sonographic features of follicular thyroid carcinoma predict biological behavior: A retrospective study. ( 30313115 )
2018
20
A Cardiac Metastasis of Follicular Thyroid Carcinoma With Partly Squamous Cell Differentiation: Detection in FDG-PET Preceded Visibility on Echocardiography and MRI by More Than a Year. ( 30325815 )
2018
21
Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study. ( 30527251 )
2018
22
Cutaneous metastasis from Hürthle cell follicular thyroid carcinoma. ( 30551968 )
2018
23
Clinicopathologic and Molecular Features of Metastatic Follicular Thyroid Carcinoma in Patients Presenting With a Thyroid Nodule Versus a Distant Metastasis. ( 30557173 )
2018
24
Thick tumor capsule is a valuable risk factor for distant metastasis in follicular thyroid carcinoma. ( 28506522 )
2018
25
Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hürthle cell carcinoma. ( 29433918 )
2018
26
LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. ( 29515098 )
2018
27
Bone metastases without primary tumor: A well-differentiated follicular thyroid carcinoma case. ( 29516937 )
2018
28
Importance of Number of Foci of Capsular Invasion in Follicular Thyroid Carcinoma. ( 29563727 )
2018
29
Overt Skeletal Metastases in a Patient of Occult (Microscopic) Follicular Thyroid Carcinoma: a Rare Case. ( 29563739 )
2018
30
CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma. ( 29581772 )
2018
31
Case report: Whole exome sequencing of circulating cell-free tumor DNA in a follicular thyroid carcinoma patient with lung and bone metastases. ( 29623111 )
2018
32
Follicular Thyroid Carcinoma in a Country of Endemic Iodine Deficiency (1994-2013). ( 29682275 )
2018
33
Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology. ( 29726952 )
2018
34
A Case of Functional Metastatic Follicular Thyroid Carcinoma that Presented with Hip Fracture and Hypercalcemia. ( 29930932 )
2018
35
Follicular Thyroid Carcinoma: A Perspective. ( 30039751 )
2018
36
Follicular thyroid carcinoma within a thyroglossal duct cyst in adult. ( 30078030 )
2018
37
Neck Ultrasound in Patients with Follicular Thyroid Carcinoma. ( 30088223 )
2018
38
Calcaneus Metastasis from Follicular Thyroid Carcinoma 12 Years after Total Thyroidectomy. ( 30228920 )
2018
39
A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy. ( 28883260 )
2017
40
Follicular thyroid carcinoma in a male adolescent with Williams-Beuren syndrome. ( 27116698 )
2017
41
Prognostic Impact of Further Treatments on Distant Metastasis in Patients With Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting. ( 27272481 )
2017
42
Metastatic follicular thyroid carcinoma: a case report. ( 27384017 )
2017
43
Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. ( 27659362 )
2017
44
Prognostic Impact of Further Treatments on Distant Metastasis in Patients with Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting. ( 27778073 )
2017
45
The total number of tissue blocks per centimetre of tumor significantly correlated with the risk of distant metastasis in patients with minimally invasive follicular thyroid carcinoma. ( 27928729 )
2017
46
Preoperative serum thyroglobulin and changes in serum thyroglobulin during TSH suppression independently predict follicular thyroid carcinoma in thyroid nodules with a cytological diagnosis of follicular lesion. ( 27936964 )
2017
47
Prognostic Impact of Further Treatments on Distant Metastasis in Patients with Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting. ( 28101608 )
2017
48
Follicular thyroid carcinoma presenting with pathological fracture of the humerus at initial diagnosis. ( 28108635 )
2017
49
Frontal bone metastasis from an occult follicular thyroid carcinoma: Diagnosed by FNAC. ( 28182063 )
2017
50
A 'silent' skull metastatic follicular thyroid carcinoma mimicking as a benign scalp tumor in a pregnant woman. ( 28203373 )
2017

Variations for Thyroid Cancer, Nonmedullary, 2

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

76
# Symbol AA change Variation ID SNP ID
1 HRAS p.Gln61Lys VAR_045979 rs28933406
2 MINPP1 p.Ser41Leu VAR_022836 rs119486096
3 MINPP1 p.Gln270Arg VAR_022837 rs104894171
4 NRAS p.Gln61Arg VAR_006847 rs11554290
5 SRGAP1 p.Gln149His VAR_075879 rs781626187
6 SRGAP1 p.Ala275Thr VAR_075880 rs797044990
7 SRGAP1 p.Arg617Cys VAR_075882 rs114817817
8 SRGAP1 p.His875Arg VAR_075883 rs61754221

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

6 (show all 32)
# Gene Variation Type Significance SNP ID Assembly Location
1 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh37 Chromosome 10, 89264794: 89264794
2 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh38 Chromosome 10, 87505037: 87505037
3 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh37 Chromosome 10, 89268264: 89268264
4 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh38 Chromosome 10, 87508507: 87508507
5 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh37 Chromosome 11, 533875: 533875
6 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh38 Chromosome 11, 533875: 533875
7 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
8 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
9 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
10 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
11 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
13 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
14 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
15 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
16 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
17 HRAS NM_005343.4(HRAS): c.520C> T (p.Pro174Ser) single nucleotide variant Benign rs397517144 GRCh37 Chromosome 11, 532686: 532686
18 HRAS NM_005343.4(HRAS): c.520C> T (p.Pro174Ser) single nucleotide variant Benign rs397517144 GRCh38 Chromosome 11, 532686: 532686
19 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh37 Chromosome 10, 89690828: 89690828
20 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh38 Chromosome 10, 87931071: 87931071
21 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs143335584 GRCh37 Chromosome 10, 89720731: 89720731
22 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs143335584 GRCh38 Chromosome 10, 87960974: 87960974
23 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh37 Chromosome 10, 89720741: 89720741
24 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh38 Chromosome 10, 87960984: 87960984
25 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh38 Chromosome 12, 64016970: 64016970
26 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh37 Chromosome 12, 64410750: 64410750
27 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh37 Chromosome 12, 64456718: 64456718
28 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh38 Chromosome 12, 64062938: 64062938
29 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh37 Chromosome 12, 64502747: 64502747
30 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh38 Chromosome 12, 64108967: 64108967
31 PTEN NM_000314.6(PTEN): c.672del (p.Tyr225Ilefs) deletion Pathogenic GRCh38 Chromosome 10, 87957890: 87957890
32 PTEN NM_000314.6(PTEN): c.672del (p.Tyr225Ilefs) deletion Pathogenic GRCh37 Chromosome 10, 89717647: 89717647

Cosmic variations for Thyroid Cancer, Nonmedullary, 2:

9 (show top 50) (show all 1391)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6961574 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 0
2 COSM7339522 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 0
3 COSM7339681 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 0
4 COSM7340098 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 0
5 COSM7339812 WT1 thyroid,NS,carcinoma,papillary carcinoma c.494C>G p.S165W 11:32428568-32428568 0
6 COSM6954354 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 0
7 COSM34008 VHL thyroid,NS,carcinoma,follicular carcinoma c.232A>T p.N78Y 3:10142079-10142079 0
8 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 0
9 COSM7340067 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1859C>A p.T620N 14:81143917-81143917 0
10 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 0
11 COSM26497 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 0
12 COSM26419 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 14:81143955-81143955 0
13 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 0
14 COSM26455 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 14:81143949-81143949 0
15 COSM26485 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 14:81143952-81143952 0
16 COSM26417 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 0
17 COSM26418 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 14:81143953-81143953 0
18 COSM26450 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 14:81143514-81143514 0
19 COSM7340068 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 0
20 COSM7339928 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4760G>A p.C1587Y 16:2086290-2086290 0
21 COSM6918838 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 0
22 COSM7340474 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4433A>T p.D1478V 16:2084655-2084655 0
23 COSM6955563 TSC1 thyroid,NS,carcinoma,follicular carcinoma c.257G>T p.R86L 9:132925693-132925693 0
24 COSM7340048 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.10688C>A p.S3563Y 7:99008440-99008440 0
25 COSM7339368 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9227T>C p.I3076T 7:98984957-98984957 0
26 COSM7340052 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.776C>G p.A259G 7:98899743-98899743 0
27 COSM6472133 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.8662C>T p.R2888C 7:98981871-98981871 0
28 COSM20429 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9809G>A p.R3270H 7:98993628-98993628 0
29 COSM7340050 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.4520C>T p.P1507L 7:98948267-98948267 0
30 COSM7340359 TRRAP thyroid,NS,carcinoma,papillary carcinoma c.7672A>C p.T2558P 7:98971853-98971853 0
31 COSM7340196 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.910G>T p.E304* 15:43477623-43477623 0
32 COSM7339759 TP53BP1 thyroid,NS,carcinoma,follicular carcinoma c.3739C>A p.R1247S 15:43428090-43428090 0
33 COSM7340198 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.5465G>T p.G1822V 15:43409017-43409017 0
34 COSM10771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 0
35 COSM10648 TP53 thyroid,NS,carcinoma,follicular carcinoma c.524G>A p.R175H 17:7675088-7675088 0
36 COSM10654 TP53 thyroid,NS,carcinoma,papillary carcinoma c.637C>T p.R213* 17:7674894-7674894 0
37 COSM10659 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 0
38 COSM10867 TP53 thyroid,NS,carcinoma,papillary carcinoma c.797G>A p.G266E 17:7673823-7673823 0
39 COSM10646 TP53 thyroid,NS,carcinoma,papillary carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
40 COSM10726 TP53 thyroid,NS,carcinoma,papillary carcinoma c.856G>A p.E286K 17:7673764-7673764 0
41 COSM11196 TP53 thyroid,NS,carcinoma,papillary carcinoma c.734G>T p.G245V 17:7674229-7674229 0
42 COSM43951 TP53 thyroid,NS,carcinoma,papillary carcinoma c.643A>G p.S215G 17:7674888-7674888 0
43 COSM43723 TP53 thyroid,NS,carcinoma,papillary carcinoma c.398T>C p.M133T 17:7675214-7675214 0
44 COSM10662 TP53 thyroid,NS,carcinoma,papillary carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
45 COSM10758 TP53 thyroid,NS,carcinoma,papillary carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
46 COSM5444226 TP53 thyroid,NS,carcinoma,papillary carcinoma c.96+1G>C p.? 17:7676381-7676381 0
47 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 17:7673761-7673761 0
48 COSM10739 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 0
49 COSM11183 TP53 thyroid,NS,carcinoma,follicular carcinoma c.799C>T p.R267W 17:7673821-7673821 0
50 COSM44922 TP53 thyroid,NS,carcinoma,papillary carcinoma c.670G>T p.E224* 17:7674861-7674861 0

Expression for Thyroid Cancer, Nonmedullary, 2

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 2.

Pathways for Thyroid Cancer, Nonmedullary, 2

Pathways related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 BRAF HRAS KDR NRAS PTEN
2
Show member pathways
12.61 BRAF HRAS NRAS PAX8 PPARG PTEN
3
Show member pathways
12.6 BRAF HRAS KDR NRAS PTEN
4 12.53 BRAF HRAS NRAS PAX8 PPARG PTEN
5
Show member pathways
12.42 DIO2 HRAS PTEN THRB
6
Show member pathways
12.36 BRAF HRAS KDR NRAS PTEN
7
Show member pathways
12.3 BRAF HRAS NRAS PTEN
8 12.2 BRAF HRAS KDR NRAS
9
Show member pathways
12.16 BRAF HRAS NRAS PPARG
10
Show member pathways
12.11 HRAS KDR NRAS PTEN
11
Show member pathways
12.04 BRAF HRAS NRAS PPARG
12 12.03 HRAS KDR NRAS PTEN
13
Show member pathways
11.99 BRAF HRAS KDR NRAS PTEN
14
Show member pathways
11.96 BRAF HRAS NRAS PTEN
15 11.84 BRAF HRAS PTEN
16 11.84 DIO2 HRAS NRAS THRB
17 11.78 BRAF HRAS NRAS PTEN
18 11.66 BRAF HRAS NRAS
19
Show member pathways
11.59 BRAF HRAS NRAS
20 11.54 BRAF HRAS NRAS
21 11.48 HRAS NRAS PTEN RET
22 11.4 HRAS NRAS RET
23
Show member pathways
11.27 BRAF HRAS KDR NRAS RET
24 11.22 BRAF HRAS NRAS
25 11.11 HRAS NRAS PTEN
26 11.09 BRAF HRAS KDR NRAS
27 10.85 BRAF HRAS MIR197 PAX8 TSHR
28 10.74 HRAS NRAS
29 10.35 TG TSHR

GO Terms for Thyroid Cancer, Nonmedullary, 2

Biological processes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.91 BRAF KDR LGALS3 PAX8 PPARG RET
2 positive regulation of gene expression GO:0010628 9.85 BRAF HRAS NKX2-1 PTEN RET
3 MAPK cascade GO:0000165 9.8 BRAF HRAS NRAS RET
4 hormone-mediated signaling pathway GO:0009755 9.58 PPARG THRB TSHR
5 animal organ morphogenesis GO:0009887 9.56 BRAF HRAS NKX2-1 THRB
6 hormone biosynthetic process GO:0042446 9.51 DIO2 TG
7 thyroid hormone metabolic process GO:0042403 9.48 DIO2 TG
8 regulation of axon regeneration GO:0048679 9.43 BRAF PTEN
9 cellular response to nerve growth factor stimulus GO:1990090 9.32 BRAF PTEN
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.26 BRAF HRAS KDR PTEN
11 thyroid-stimulating hormone signaling pathway GO:0038194 9.16 PAX8 TSHR
12 thyroid gland development GO:0030878 9.02 BRAF NKX2-1 PAX8 TG THRB
13 signal transduction GO:0007165 10.13 BRAF HRAS NRAS PPARG RET SRGAP1

Molecular functions related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.46 PPARG RET THRB TSHR
2 inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity GO:0051717 8.96 MINPP1 PTEN
3 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Thyroid Cancer, Nonmedullary, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....